ADVANCED
IMMUNOTHERAPEUTICS
FOR LIFE SCIENCES
Leveraging the Revolutionary Science of Checkpoint Inhibitors to Create Turbocharged Vaccines for Animal and Human Health
MBF Therapeutics is a life science company focused on the development of gene-based, immunotherapeutic vaccines for use in veterinary medicine and human health. Using proprietary vaccine platform & delivery system technology, MBF Therapeutics’ checkpoint inhibitor therapies have the potential of transforming the treatment of cancer and prevention of infectious diseases.

THE LATEST IN THE
NEWS:
Partnership Opportunities with MBF Therapeutics
In addition to developing effective therapeutic and prophylactic vaccines for unmet needs in animal health, the MBF Therapeutics team is dedicated to delivering long-term value to our investors by leveraging key partnerships with various research institutions, clinical testing facilities and a USDA licensed manufacturer.
MBF Therapeutics—The First Company to Develop an Animal Health Vaccine Using Gene-based Checkpoint Inhibitors
MBF Therapeutics’ lead product is an immunotherapeutic vaccine for canine melanoma. Two pilot studies have been completed and the vaccine:
-
Was shown to be safe
-
Elicited a robust immune response in 100% of dogs treated
-
Has potential for a conditional registration as early as 2020.
MBF Therapeutics also has a strong pipeline of products, including vaccines for other cancers in companion animals, as well as economically significant infectious swine diseases.
